

Jinoos Yazdany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4075348/publications.pdf>

Version: 2024-02-01

175
papers

9,610
citations

81900

39
h-index

45317

90
g-index

180
all docs

180
docs citations

180
times ranked

10835
citing authors

#	ARTICLE	IF	CITATIONS
1	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care and Research</i> , 2012, 64, 797-808.	3.4	1,119
2	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
3	Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data. <i>JAMA Internal Medicine</i> , 2018, 178, 1544.	5.1	693
4	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. <i>Arthritis Care and Research</i> , 2012, 64, 640-647.	3.4	566
5	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
6	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2020, 72, 529-556.	5.6	332
7	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 143.	3.5	180
8	Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. <i>Annals of Internal Medicine</i> , 2020, 172, 754-755.	3.9	176
9	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
10	Depression, medication adherence, and service utilization in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 240-246.	6.7	163
11	Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. <i>Science</i> , 2022, 376, eabf1970.	12.6	156
12	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
13	Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2019, 2, e190606.	5.9	135
14	A quality indicator set for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 370-377.	6.7	122
15	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , 2020, 72, 461-488.	3.4	122
16	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
17	Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 480.	7.4	120
18	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	8.0	105

#	ARTICLE	IF	CITATIONS
19	Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. <i>Arthritis and Rheumatism</i> , 2008, 59, 136-143.	6.7	102
20	Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. <i>Arthritis Care and Research</i> , 2013, 65, 329-339.	3.4	89
21	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
22	Brief index of lupus damage: A patient-reported measure of damage in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1170-1177.	3.4	86
23	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
24	The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. <i>Nature Reviews Rheumatology</i> , 2020, 16, 293-294.	8.0	85
25	Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. <i>Arthritis Care and Research</i> , 2020, 72, 622-629.	3.4	77
26	Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality?. <i>Arthritis Care and Research</i> , 2011, 63, 358-365.	3.4	76
27	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1386-1388.	0.9	67
28	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	5.6	66
29	Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	3.4	61
30	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , 2017, 37, 1249-1255.	3.0	61
31	The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 1782-8.	2.0	60
32	Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 593-600.	6.7	59
33	Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R84.	3.5	59
34	Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospital- and State-Level Variation. <i>Arthritis and Rheumatology</i> , 2014, 66, 2828-2836.	5.6	54
35	Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. <i>Arthritis and Rheumatology</i> , 2015, 67, 1474-1480.	5.6	50
36	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49

#	ARTICLE	IF	CITATIONS
37	Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. <i>Current Opinion in Rheumatology</i> , 2020, 32, 434-440.	4.3	46
38	Quality of Care for Incident Lupus Nephritis Among Medicaid Beneficiaries in the United States. <i>Arthritis Care and Research</i> , 2014, 66, 617-624.	3.4	44
39	Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (Lâ€QoL). <i>Arthritis Care and Research</i> , 2011, 63, S413-9.	3.4	43
40	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	3.4	43
41	Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. <i>Arthritis Care and Research</i> , 2010, 62, 993-1001.	3.4	42
42	Quality of Care in Systemic Lupus Erythematosus: Application of Quality Measures to Understand Gaps in Care. <i>Journal of General Internal Medicine</i> , 2012, 27, 1326-1333.	2.6	41
43	A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1612-1622.	5.6	41
44	Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials. <i>JAMA Network Open</i> , 2019, 2, e1914745.	5.9	41
45	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
46	Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 542-549.	3.4	39
47	2019 American College of Rheumatology Recommended Patient-reported Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 1531-1539.	3.4	39
48	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. <i>Nature Communications</i> , 2019, 10, 3902.	12.8	39
49	Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. <i>Npj Digital Medicine</i> , 2020, 3, 57.	10.9	38
50	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
51	Defining quality of care in rheumatology: The American College of Rheumatology white paper on quality measurement. <i>Arthritis Care and Research</i> , 2011, 63, 2-9.	3.4	37
52	Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. <i>BMJ Quality and Safety</i> , 2014, 23, 659-666.	3.7	37
53	National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0144918.	2.5	37
54	Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1101-1106.	3.4	37

#	ARTICLE	IF	CITATIONS
55	Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 61-65.	4.4	37
56	Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1087-1092.	3.4	37
57	Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. <i>RMD Open</i> , 2020, 6, e001247.	3.8	35
58	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 386-392.	3.4	34
59	The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. <i>Rheumatology</i> , 2020, 59, 1204-1206.	1.9	34
60	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
61	Quality measurement and improvement in rheumatology: Rheumatoid arthritis as a case study. <i>Arthritis and Rheumatism</i> , 2011, 63, 3649-3660.	6.7	33
62	Validity and Responsiveness of a 10-item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. <i>Arthritis Care and Research</i> , 2017, 69, 338-346.	3.4	32
63	Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 927-932.	3.4	32
64	Patient-reported outcome measures for use in clinical trials of SLE: a review. <i>Lupus Science and Medicine</i> , 2018, 5, e000279.	2.7	32
65	Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2020, 2, 53-60.	2.1	32
66	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358.	1.9	32
67	Using human centered design to empower rheumatoid arthritis patients through patient reported outcomes. <i>Patient Education and Counseling</i> , 2019, 102, 503-510.	2.2	31
68	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
69	Quality of care in the rheumatic diseases: current status and future directions. <i>Current Opinion in Rheumatology</i> , 2008, 20, 159-166.	4.3	29
70	Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 193-200.	3.4	29
71	Health-Related Quality of Life and Employment Among Persons with Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 15-32.	1.9	29
72	Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safety-Net Health Setting. <i>Arthritis Care and Research</i> , 2015, 67, 1158-1163.	3.4	29

#	ARTICLE	IF	CITATIONS
73	Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 267-272.	3.4	29
74	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2021, 4, e2119400.	5.9	29
75	Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 931.	7.4	27
76	Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. <i>JAMA Internal Medicine</i> , 2017, 177, 585.	5.1	25
77	Does Systemic Lupus Erythematosus Care Provided in a Lupus Clinic Result in Higher Quality of Care Than That Provided in a General Rheumatology Clinic?. <i>Arthritis Care and Research</i> , 2018, 70, 1771-1777.	3.4	25
78	Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey. <i>Arthritis Care and Research</i> , 2020, 72, 871-873.	3.4	25
79	Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort. <i>Arthritis Care and Research</i> , 2021, 73, 48-54.	3.4	25
80	Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. <i>Communications Biology</i> , 2021, 4, 488.	4.4	25
81	American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology. <i>Arthritis Care and Research</i> , 2016, 68, 1390-1401.	3.4	24
82	Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 525-533.	3.4	24
83	Impact of Limited Health Literacy on Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2021, 73, 110-119.	3.4	24
84	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. <i>Journal of Rheumatology</i> , 2022, 49, 320-329.	2.0	24
85	Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. <i>Journal of Rheumatology</i> , 2015, 42, 1616-1623.	2.0	23
86	Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002800.	8.4	23
87	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1004-1006.	0.9	23
88	Type I interferon, anti-interferon antibodies, and COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e246-e247.	3.9	23
89	Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 1630-1639.	3.4	22
90	Post-marketing Experiences with Belimumab in the Treatment of SLE Patients. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 507-517.	1.9	21

#	ARTICLE	IF	CITATIONS
91	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 467-474.	2.2	21
92	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 9-21.	8.0	21
93	Using Medicare Data to Understand Low-Value Health Care. <i>JAMA Internal Medicine</i> , 2014, 174, 1702.	5.1	20
94	Receipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1447-1455.	3.4	19
95	Using Health Information Technology to Support Use of Patient-Reported Outcomes in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 257-273.	1.9	19
96	Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates. <i>Journal of Rheumatology</i> , 2019, 46, 370-375.	2.0	19
97	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021, 232, 49-59.	5.0	19
98	Factors associated with access to rheumatologists for Medicare patients. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 511-518.	3.4	18
99	Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators. <i>Arthritis Care and Research</i> , 2011, 63, 17-30.	3.4	17
100	Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016. <i>Arthritis Care and Research</i> , 2021, 73, 1444-1450.	3.4	17
101	Patient and clinician perspectives on a patient-facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis. <i>Health Expectations</i> , 2020, 23, 846-859.	2.6	17
102	Leveraging the electronic health record to improve quality and safety in rheumatology. <i>Rheumatology International</i> , 2017, 37, 1603-1610.	3.0	17
103	Preventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines?. <i>Arthritis Care and Research</i> , 2010, 62, 585-589.	3.4	16
104	Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 95-107.	0.3	16
105	Interactions Between Patients, Providers, and Health Systems and Technical Quality of Care. <i>Arthritis Care and Research</i> , 2015, 67, 417-424.	3.4	16
106	RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1542-1548.	3.4	15
107	Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States. <i>Arthritis and Rheumatology</i> , 2020, 72, 870-873.	5.6	15
108	Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. <i>Arthritis Care and Research</i> , 2021, 73, 146-157.	3.4	15

#	ARTICLE	IF	CITATIONS
109	Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries. <i>Arthritis Care and Research</i> , 2015, 67, 1210-1218.	3.4	14
110	Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study. <i>BMC Health Services Research</i> , 2016, 16, 499.	2.2	14
111	Significant Gains in Rheumatoid Arthritis Quality Measures Among RISE Registry Practices. <i>Arthritis Care and Research</i> , 2022, 74, 219-228.	3.4	14
112	Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. <i>JMIR Medical Informatics</i> , 2018, 6, e31.	2.6	14
113	Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. <i>Arthritis Research and Therapy</i> , 2015, 17, 367.	3.5	13
114	Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1402-1409.	3.4	13
115	Race, Ethnicity, and Disparities in the Risk of Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. <i>Arthritis Care and Research</i> , 2023, 75, 34-43.	3.4	13
116	Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 363-375.	1.9	12
117	Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab. <i>Medicine (United States)</i> , 2017, 96, e6528.	1.0	12
118	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	3.0	12
119	Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 623-638.	1.9	12
120	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. <i>Current Opinion in Rheumatology</i> , 2021, 33, 111-116.	4.3	12
121	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. <i>Rheumatology International</i> , 2017, 37, 1611-1618.	3.0	11
122	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: "Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials: a real-world district general hospital experience" by K. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-218713.	0.9	11
123	Increased Risk of Ischemic Stroke in Systemic Sclerosis: A National Cohort Study of US Veterans. <i>Journal of Rheumatology</i> , 2020, 47, 82-88.	2.0	10
124	Race, Ethnicity and Disparities in Rheumatology Educational Materials. <i>Arthritis Care and Research</i> , 2021, , .	3.4	10
125	Epidemiology and treatment of Behçet's disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. <i>Arthritis Research and Therapy</i> , 2021, 23, 224.	3.5	10
126	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. <i>Global Rheumatology</i> , 0, , .	0.0	10

#	ARTICLE	IF	CITATIONS
127	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88.	0.6	10
128	Development of a Natural Language Processing System for Extracting Rheumatoid Arthritis Outcomes From Clinical Notes Using the National Rheumatology Informatics System for Effectiveness Registry. <i>Arthritis Care and Research</i> , 2023, 75, 608-615.	3.4	10
129	Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis. <i>Pediatric Rheumatology</i> , 2018, 16, 30.	2.1	9
130	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
131	The Evolving Art and Science of American College of Rheumatology Guidelines. <i>Arthritis and Rheumatology</i> , 2019, 71, 2-4.	5.6	8
132	COVID-19 in Rheumatic Diseases: A Research Agenda. <i>Arthritis and Rheumatology</i> , 2020, 72, 1596-1599.	5.6	8
133	Treatment of Sarcoidosis in <sc>US</sc> Rheumatology Practices: Data From the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (<sc>RISE</sc>) Registry. <i>Arthritis Care and Research</i> , 2022, 74, 371-376.	3.4	8
134	Response to: â€˜Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosisâ€™ by GyÅŕfi <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e88-e88.	0.9	8
135	High Disease Severity Among Asians in a US Multiethnic Cohort of Individuals with Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, , .	3.4	8
136	Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic. <i>BMC Health Services Research</i> , 2016, 16, 384.	2.2	7
137	Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study. <i>Arthritis Care and Research</i> , 2020, 72, 283-291.	3.4	7
138	Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings. <i>Arthritis Care and Research</i> , 2020, 72, 888-896.	3.4	7
139	Response to: Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritisâ€ by van Vollenhoven<i> et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.9	7
140	The impact of COVID-19 on rheumatology trainingâ€™ results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rrac001.	0.7	7
141	Influence of Continuing Medical Education on Rheumatologistsâ€™ Performance on National Quality Measures for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2015, 2, 141-151.	2.3	6
142	Accurate Measurement In Californiaâ€™s Safety-Net Health Systems Has Gaps And Barriers. <i>Health Affairs</i> , 2018, 37, 1760-1769.	5.2	6
143	Quality improvement initiatives in rheumatology: an integrative review of the last 5 years. <i>Current Opinion in Rheumatology</i> , 2019, 31, 98-108.	4.3	6
144	Rapid Adoption of Telemedicine in Rheumatology Care During the <sc>COVID</sc>-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	2.1	6

#	ARTICLE	IF	CITATIONS
145	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry™ by Gianfrancesco et al</i>. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases™ by Giollo et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e223-e223.	0.9	5
146	Quality of Care for Patients With Systemic Lupus Erythematosus: Data From the American College of Rheumatology <scp>RISE</scp> Registry. Arthritis Care and Research, 2022, 74, 179-186.	3.4	5
147	Response to: â€˜Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquineâ€™™ by Carbillon et al</i>. Annals of the Rheumatic Diseases, 2021, 80, e55-e55.	0.9	5
148	Physical Inactivity and Incident Depression in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care and Research, 2022, 74, 1098-1104.	3.4	5
149	The Development of the Rheumatology Informatics System for Effectiveness Learning Collaborative for Improving Patientâ€™Reported Outcome Collection and Patientâ€™Centered Communication in Adult Rheumatology. ACR Open Rheumatology, 2021, 3, 690-698.	2.1	5
150	Factors Associated With Hospitalization and Death After COVIDâ€™19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. ACR Open Rheumatology, 2021, 3, 796-803.	2.1	5
151	Dynamics of Methylation of <scp>CpG</scp> Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	5.6	5
152	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4
153	Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. PLoS ONE, 2016, 11, e0168369.	2.5	4
154	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatologyâ€™s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
155	Racial and ethnic differences in COVID-19 outcomes: a call to action. Lancet Rheumatology, The, 2022, 4, e455-e457.	3.9	4
156	Underestimation of the Reliability of Codes for Rheumatoid Arthritis Within Administrative Data: Comment on the Article by Ng et al. Arthritis Care and Research, 2013, 65, 835-836.	3.4	3
157	Scleroderma and Pelvic Organ Prolapse: A Multidisciplinary Approach to Patient Care and Surgical Planning. Journal of Gynecologic Surgery, 2017, 33, 198-201.	0.1	3
158	The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101665.	3.3	3
159	Response to: Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registryâ€™™ by Sparks et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e158-e158.	0.9	3
160	Does Higher Quality of Care in Systemic Lupus Erythematosus Improve Quality of Life?. Arthritis Care and Research, 2023, 75, 1198-1205.	3.4	3
161	Improving Patient Safety in Public Hospitals. Journal of Patient Safety, 2018, Publish Ahead of Print, e773-e790.	1.7	2
162	Reweighting to address nonparticipation and missing data bias in a longitudinal electronic health record study. Annals of Epidemiology, 2020, 50, 48-51.e2.	1.9	2

#	ARTICLE	IF	CITATIONS
163	Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic. <i>Journal of Rheumatology</i> , 2020, 47, 1712-1720.	2.0	2
164	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
165	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
166	Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. <i>European Journal of Rheumatology</i> , 2023, 9, 185-190.	0.6	2
167	The impact of smoking on disease measures in rheumatoid arthritis: the need for appropriate adjustment of time-varying confounding. <i>Rheumatology International</i> , 2018, 38, 313-314.	3.0	1
168	Further Lessons in Pneumocystis Pneumonia Prophylaxis. <i>JAMA Internal Medicine</i> , 2018, 178, 1565.	5.1	1
169	Reimagining Rheumatology: Big Data and the Future of Clinical Practice and Research. <i>Arthritis Care and Research</i> , 2020, 72, 163-165.	3.4	1
170	Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. <i>Journal of Rheumatology</i> , 2021, , jrheum.211000.	2.0	1
171	Predictors of <sc>Thirty-Day</sc> Hospital Readmissions in Systemic Lupus Erythematosus in the <sc>US</sc> : A Nationwide Study. <i>Arthritis Care and Research</i> , 2022, , .	3.4	1
172	Using Medicare Data to Understand Health Care Value"Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 462.	5.1	0
173	Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment. <i>JAMA Neurology</i> , 2020, 77, 933.	9.0	0
174	Shifting knowledge and attitudes about biosimilars among rheumatologists. <i>Rheumatology</i> , 2021, 60, 492-493.	1.9	0
175	Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2022, , .	2.1	0